Berbice Capital Management LLC Purchases Shares of 260 HCA Healthcare, Inc. (NYSE:HCA)

Berbice Capital Management LLC purchased a new position in HCA Healthcare, Inc. (NYSE:HCA) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 260 shares of the company’s stock, valued at approximately $78,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of HCA Healthcare during the 2nd quarter worth approximately $33,000. Legacy Investment Solutions LLC acquired a new stake in shares of HCA Healthcare during the 3rd quarter worth approximately $39,000. Canoe Financial LP acquired a new stake in shares of HCA Healthcare during the 3rd quarter worth approximately $41,000. Capital Performance Advisors LLP purchased a new position in shares of HCA Healthcare during the 3rd quarter valued at approximately $41,000. Finally, Northwest Investment Counselors LLC purchased a new position in shares of HCA Healthcare during the 3rd quarter valued at approximately $44,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Transactions at HCA Healthcare

In related news, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the transaction, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Performance

NYSE HCA opened at $325.54 on Friday. The company has a market cap of $82.46 billion, a P/E ratio of 14.47, a P/E/G ratio of 1.09 and a beta of 1.64. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. The stock has a 50-day moving average of $314.50 and a two-hundred day moving average of $352.84. HCA Healthcare, Inc. has a 1-year low of $279.93 and a 1-year high of $417.14.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period in the prior year, the company posted $5.90 earnings per share. As a group, analysts anticipate that HCA Healthcare, Inc. will post 21.75 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on HCA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $392.00 target price on shares of HCA Healthcare in a research report on Tuesday, October 1st. StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Barclays decreased their price objective on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Wells Fargo & Company lowered HCA Healthcare from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $400.00 to $320.00 in a report on Monday, November 25th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $380.00 target price on shares of HCA Healthcare in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $385.27.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.